Mössbauer spectroscopy and ELISA studies reveal differences between Parkinson's disease and control substantia nigra

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1688, Issue 2, 2004, Pages 130-136

  Galazka Friedman, Jolanta ^a   Bauminger, Erika R ^b   Koziorowski, Dariusz ^c   Friedman, Andrzej ^c  

^a WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

ELISA; Ferritin; M ssbauer spectroscopy; Nigral iron; Oxidative stress; Parkinson's disease

Indexed keywords

FERRITIN; IRON; NEUROMELANIN; PROTEIN SUBUNIT;

AGED; ARTICLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IRON KINETICS; MOSSBAUER SPECTROSCOPY; NERVE CELL DEGENERATION; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

PARKINSONIA;

EID: 1342285717     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2003.11.005     Document Type: Article

References (38)

1. Hallgren B., Sourander P. The effect of age on the non-haemin iron in the human brain. J. Neurochem. 3:1958;41-51.
2. Halliwell B. Oxygen radicals as key mediators in neurological disease: fact or fiction. Ann. Neurol. 32:1992;S10-S15.
3. Griffiths P.D., Dobson B.R., Jones G.R., Clarke D.T. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain. 122:1999;667-673.
4. Harrison P.M., Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta. 1275:1996;161-203.
5. Chasteen N.D., Harrison P.M. Mineralization in ferritin: an efficient means of iron storage. J. Struct. Biol. 126:1999;182-194.
6. Zecca L., Gallorini M., Schuenemann V., Trautwein A.X., Gerlach M., Riederer P., Vezzoni P., Tampellini D. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76:2001;1766-1773.
7. Connor J.R., Snyder B.S., Arosio P., Loeffler D.A., LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 65:1995;717-724.
8. Eggleton R.A., Fitzpatrick R.W. New data and a revised structural model for ferrihydrite. Clays Clay Miner. 36:1988;111-114.
9. Zecca L., Tampellini D., Gerlach M., Riederer P., Fariello R.G., Sulzer D. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. J. Clin. Pathol.: Mol. Pathol. 54:2001;414-418.
10. Moos T. Absence of ferritin protein in substantia nigra pars compacta neuron. A reappraisal to the role of iron in Parkinson disease pathogenesis. Mov. Disord. 15(Suppl. 3):2000;319A.
11. Connor J.R., Boyer P.J., Menzies S.L., Dellinger B., Allen R.P., Ondo W.G., Earley C.J. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology. 61:2003;304-309.
12. Gerlach M., Trautwein A.X., Zecca L., Youdim M.B.H., Riederer P. Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. J. Neurochem. 65:1995;923-926.
13. Aime S., Bergamasco B., Biglino D., Digilio G., Fasano M., Giarnello E., Lopiano L. EPR investigations of the iron domain in neuromelanin. Biochim. Biophys. Acta. 1361:1997;49-58.
14. Galazka-Friedman J., Bauminger E.R., Friedman A., Barcikowska M., Hechel D., Nowik I. Iron in parkinsonian and control substantia nigra - A Mössbauer spectroscopy study. Mov. Disord. 11:1996;8-16.
15. Galazka-Friedman J., Bauminger E.R., Friedman A. Iron in Parkinson's disease revisited. Hyperfine Interact. 141/142:2002;267-271.
16. Morup S. Mössbauer effect in small particles. Hyperfine Interact. 60:1990;959-974.
17. Bell S.H., Weir M.P., Dickson D.P.E., Gibbson J.F., Sharp G.A., Peters T.J. Mössbauer spectroscopic studies of human haemosiderin and ferritin. Biochim. Biophys. Acta. 787:1984;227-236.
18. Murad E., Johnstone J.H. Iron oxides and oxyhydroxides. Long G.J. Mössbauer Spectroscopy Applied to Inorganic Chemistry. vol. 2:1987;542-547 Plenum, New York.
19. Oshtrakh M.I., Semionkin V.A., Prokopenko P.G., Milder O.B., Livshits A.B., Kozlov A.A. Hyperfine interactions in the iron cores from various pharmaceutically important iron-dextran complexes and human ferritin: a comparative study by Mössbauer spectroscopy. Int. J. Biol. Macromol. 29:2001;303-314.
20. Dexter D.T., Carayon A., Vidailhet M., Ruberg M., Agid F., Agid Y., Lees A.J., Wells F.R., Jenner P., Marsden C.D. Decreased ferritin levels in brain in Parkinson's disease. J. Neurochem. 55:1990;16-20.
21. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B.H. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520.
22. Mann V.M., Cooper J.M., Daniel S.E., Srai K., Jenner P., Marsden C.D., Schapira A.H. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann. Neurol. 36:1994;876-881.
23. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology. 17:1967;427-442.
24. Luzzago A., Arosio P., Iacobello C., Ruggeri G., Capucci L., Brocchi E., De Simone F., Gamba D., Gabri E., Levi S., Albertini A. Immunochemical characterization of human liver and heart ferritins with monoclonal antibodies. Biochim. Biophys. Acta. 872:1986;61-71.
25. Arosio P., Cozzi A., Levi S., Luzzago A., Ruggeri G., Iacobello C., Santambrogio P., Albertini A. A mutantional analysis of the epitops of recombinant human H-ferritin. Biochim. Biophys. Acta. 1039:1990;197-203.
26. Koziorowski D., Friedman A., Galazka-Friedman J. Ferritin in parkinsonian and control brains. J. Neurochem. 85(Suppl. 2):2003;29.
27. Thorpe S.J., Walker D., Arosio P., Heath A., Cook J., Worwood M. International collaborative study to evaluate a recombinant L ferritin preparation as an International Standard. Clin. Chem. 43:1997;1582-1587.
28. Winer B.J. Statistical Principal in Experimental Design. 1962;33-39 McGraw-Hill, San Francisco.
29. Olas B., Wachowicz B., Mielicki W.P., Byczynski A. Free radicals are involved in cancer procoagulant-induced platelet activation. Thromb. Res. 97:2000;169-175.
30. Shiraishi T., Sasaki K., Niijima A., Oomura Y. Leptin effects on feeding-related hypothalamic and peripheral neuronal activities in normal and obese rats. Nutrition. 15:1999;576-579.
31. Chua-anusorn W., Webb J., Macey D.J., Pootrakul P., Pierre St.T.G. The effect of histological processing on the form of iron in iron-loaded human tissues. Biochim. Biophys. Acta. 1360:1997;255-261.
32. Pierre St.T.G., Chan P., Bauchspiess P., Webb J., Betteridge S., Walton S., Dickson D.P.E. Synthesis, structure and magnetic properties of ferritin cores with varying composition and degrees of structural order: models for iron oxide deposits in iron-overload diseases. Coord. Chem. Rev. 151:1996;125-143.
33. Zecca L., Fariello R., Riederer P., Sulzer D., Gatti A., Tampellini D. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett. 510:2002;216-220.
34. Lopiano L., Chiesa M., Digilio G., Giraudo S., Bergamasco B., Torre E., Fasano M. Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients. Biochim. Biophys. Acta. 1500:2000;306-312.
35. Bolzoni F., Giraudo S., Lopiano L., Begamesco B., Fasano M., Crippa P.R. Magnetic investigations of human mesencephalic neuromelanin. Biochim. Biophys. Acta. 1586:2002;210-218.
36. Faucheux B.A., Martin M.E., Beaumont C., Hunot S., Hauw J.J., Hirsch E.C. Lack of upregulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 83:2002;320-330.
37. Smith M.A., Harris P.L.R., Sayre L.M., Perry G. Iron accumulation in Alzheimer disease is a source of redox generated free radicals. Proc. Natl. Acad. Sci. U. S. A. 94:1997;9866-9868.
38. Uitti R.J., Rajput A.H., Rozdilsky B., Bickis M., Wollin T., Yuen W.K. Regional metal concentration in Parkinson's disease, other chronic neurological diseases, and control brains. Can. J. Neurol. Sci. 16:1989;310-314.